Taux d'Incidence des Pneumopathies Interstitielles Chez les Patients Atteints de Polyarthrite Rhumatoïde Traités au Tofacitinib
Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.This study highlights the importance of accounting for known risk factors of RA-ILD in clinical practice. Interstitial lung disease (ILD) is an extra-articular manifestation of RA. The post-hoc investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and identified potential risk factors for ILD. This post-hoc analysis comprised a pooled analysis of patients receiving tofacitinib 5 or 10 mg twice daily or placebo from 21 Phase 1-4, and 2 long-term ex...